Table 1.
Summary of Key Clinical, Pathologic, and Molecular Characteristics and Outcomes of Study Patients
| Pt ID | Age | Gender | Histology | EGFR Mutation | Resistance Mechanism | Prior EGFR TKI | Baseline PD-L1 Expression (22C3) | Best Response | PFS (d) | irAE |
|---|---|---|---|---|---|---|---|---|---|---|
| UCD-001 | 82 | M | Squamous | E19del | Unknown | Erlotinib | 40% | PR | 344 | Yes (G2 nephritis) |
| UCD-002 | 65 | M | Adenocarcinoma | E19del | MET amp | Erlotinib | 20% | SD | 81 | No |
| UCD-003 | 39 | F | Adenocarcinoma | E19del | Unknown | Erlotinib | QNS | SD | 27 | No |
| UCD-004 | 83 | M | Adenocarcinoma | L858R | T790M | Erlotinib | 1% | SD | 510 | Yes (G2 adrenal insufficiency) |
| UCD-005 | 47 | M | Neuroendocrine Carcinoma |
L858R | HER2 amp (neuroendocrine) | Erlotinib | 0% | PD | 35 | No |
| UCD-006 | 75 | F | Adenocarcinoma | E19del | T790M | Erlotinib, osimertinib | 10% | SD | 77 | No |
| UCD-007 | 69 | F | Adenocarcinoma | L861Q | Unknown | Erlotinib | 25% | SD | 186 | Yes (G3 colitis) |
| UCD-008 | 53 | F | Adenocarcinoma | E19del | T790M | Erlotinib, osimertinib | 75% | PD | 7 | No |
| UCD-009 | 70 | F | Adenocarcinoma | E19del | T790M/C797S | Erlotinib, osimertinib | 30% | PD | 8 | No |
| UCD-010 | 76 | F | Adenocarcinoma | L858R | Unknown | Erlotinib, osimertinib | QNS | SD | 84 | No |
| UCD-011 | 62 | F | Adenocarcinoma | L858R | MET amp | Erlotinib | 90% | PR | > 42 | Yes (G3 colitis) |
G, grade; PD, progressive disease; PD-L1, programmed death-ligand 1; PFS, progression-free survival; PR, partial response; SD, stable disease; TKI, tyrosine kinase inhibitor.